Targeted therapy- other Flashcards
1
Q
Erdafitinib
A
FGFR2/3 mutation/fusion
Metastatic urothelial cancer
2
Q
Pemigatinib
A
FGF2 fusion
Previously treated metastatic cholangio
3
Q
Selpercatinib
A
RET fusion/mutation
Thyroid
NSCLC
4
Q
Pralsetinib
A
RET fusion
NSCLC
5
Q
Alpelisib
A
PIK3CA mutation
Post-menopausal women/men with HR+, HER2- metastatic breast cancer
6
Q
Avapritinib
A
PDGFRA exon 18 mutation
Unresectable/metastatic GIST
7
Q
Tazemetostat
A
EZH2 mutation
SMARCA mutation
Metastatic epithelioid sarcoma
8
Q
Olaparib
A
BRCA1/2 mutation 2nd line metastatic breast 4th line metastatic ovarian Recurrent/advanced ovarian maintenance Prostate Pancreatic
9
Q
Rucaparib
A
BRCA1/2 mutation
3rd line metastatic ovarian
Recurrent ovarian maintenance
Prostate
10
Q
Talazoparib
A
BRCA1/2
Metastatic breast
11
Q
Dabrafenib
A
BRAF V600E/K
Melanoma
NSCLC
Anaplastic thyroid
12
Q
Vemurafenib
A
BRAF V600E/K
Melanoma
13
Q
Encorafenib
A
BRAF V600E/K
Melanoma
Colon
14
Q
Trametinib
A
MEK inhibitor Only approved in combo with dabrafenib Melanoma NSCLC Anaplastic thyroid
15
Q
Cobimetinib
A
MEK inhibitor
Only approved in combo with vemurafenib
Melanoma
